Vaccine capacity grows
This article was originally published in The Gold Sheet
Executive Summary
FDA recently approved two influenza virus vaccine production facilities. The agency approved a new bulk manufacturing site for Sanofi Pasteur on May 6 as well as an additional manufacturing site for CSL Ltd. on Aug. 17. Expanded production capacity could be used later on the H1N1 virus, once there are vaccines against it